Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected Data
ByAlberto Calvo-García, PharmG,María Pérez Abánades, PharmG,Silvia Ruíz-García, PharmG,Ana Beatriz Fernández Román, PharmG,Javier Letellez Fernández, PharmG,Beatriz Candel García, PharmG,Carlos Hernández Terciado, PharmG,Raquel De Santiago Álvarez, PharmG,Rebeca Mondéjar Solis, MD,Berta Hernández Marin, MD,Patricia Toquero Diez, MD,Alberto Morell Baladrón, PharmG,Ramón Colomer Bosch, MD
Alberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
